Liquid Biopsy
Liquid biopsy is a non-invasive sampling technique that can be used to detect genetic abnormalities and and improve patient management.
What are the benefits?
When tissue biopsy is not possible, recommended or feasible within an acceptable timeframe, circulating tumor DNA analysis is a recognized alternative for the diagnosis, prognosis, therapeutic orientation, follow-up and recurrence of cancer patients.
What is the purpose of this kind of sampling?
For most cancers, a simple blood test can be used to detect genomic alterations or tumor heterogeneity, with shorter turnaround times for results, and therefore a shorter patient pathway.
Ordering information
Pascual et al. ESMO recommandations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Annals of Oncology, 2022 Vol. 33, Issue 8
Rolfo et al. Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer. J Thorac. Oncol; 2021;16: 1647-1662
Garlan et al. Early evaluation of circulating tumor DNA as marker of therapeutic efficacy in metastacic colorectal cancer patients (PLACOL Study). Clin Cancer Res. 2017; 23:5416-5425
Bratman et al. Personalizes circulating tumor DNA analysis as a predictive biomarker in solid tumor patients trated with pembrolizumab. Nature Cancer, 2020;1:873-881
